Retatrutide

Retatrutide is a new entrant into the rapidly-expanding space of anti-obesity peptides. It is known as a GGG tri- agonist. This means that Retatrutide works at all of the incretin receptors including GLP-1 and GIP as well as the glucagon receptor itself. Research indicates that retatrutide may be the most effective weight loss peptide yet developed, with some studies showing a rapid and sustained weight loss response as high as 24% of total body weight. Retatrutide is thought to promote weight loss by increasing energy expenditure as well as decreasing energy consumption. It does the former via action at the glucagon receptor and the latter through both central and peripheral appetite control.

How Does Retatrutide Work?

In vivo research, in humans, indicates that retatrutide activates and is a full agonist of all of the incretin receptors including GIPR, GLP-1R, and GCGR. Retatrutide was specifically designed to be highly potent at the GIPR and GLP-1R locations. As a result, retatrutide is one of the most potent incretins available and thus has strong effects on both gastric emptying and the central control of hunger/satiety. Research shows that the bulk of retatrutide’s effects are driven by loss of fat mass that is probably the result of a larger and more prolonged reduction in food intake compared to similar peptides. Decreased food intake, especially as occurs early in the use of the peptide, jump starts fat oxidation. This sets the stage for prolonged weight loss by altering basal metabolism and overcoming the hormonal forces that perpetuate obesity.

The bulk of retatrutide’s benefit is a result of its ability to decrease energy intake via delayed gastric emptying and increased control of hunger signals in the central nervous system.

Dosage:


Retatrutide is sold in vials containing 10MG of lyophilised powder which should be stored under refrigeration. (It is acceptable however for them to be mailed unrefrigerated). The contents can be reconstituted by adding a convenient amount of sterile or bacteriostatic water.

When 10 mg of retatrutide is reconstituted with 2 mL of bacteriostatic water, the solution has a concentration of 5,000 mcg per mL.

On a standard insulin syringe (100 IU = 1 mL):

1 IU = 50 mcg
A 100 mcg (0.1 mg) dose = 2 IU (0.02 mL)
A 500 mcg dose = 10 IU (0.1 mL)
A 1,000 mcg (1 mg) dose = 20 IU (0.2 mL)

At time of dosing, an insulin syringe is used to draw and then inject the desired amount.
In the above example a 100mcg (or 0.1mg) dose would require 0.1mL, or “10 IU” as marked on an insulin syringe.

Retatrutide is generally administered once weekly, at dosages of 1000mcg per administration, for 12-24 weeks. Dosage can be increased to 2mg after 12 weeks.